Scinai Immunotherapeutics (NASDAQ:SCNI) Issues Quarterly Earnings Results

Scinai Immunotherapeutics (NASDAQ:SCNI) posted its quarterly earnings results on Monday. The company reported ($0.74) earnings per share (EPS) for the quarter, Zacks reports.

Scinai Immunotherapeutics Price Performance

SCNI opened at $3.22 on Monday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.35 and a quick ratio of 1.35. The stock’s 50 day simple moving average is $2.67 and its 200 day simple moving average is $5.03. The firm has a market cap of $1.67 million, a price-to-earnings ratio of -3.04 and a beta of 2.08. Scinai Immunotherapeutics has a 1 year low of $2.15 and a 1 year high of $17.20.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Institutional Trading of Scinai Immunotherapeutics

A hedge fund recently raised its position in Scinai Immunotherapeutics stock. Citadel Advisors LLC boosted its position in Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) by 146.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 28,630 shares of the company’s stock after acquiring an additional 17,031 shares during the period. Citadel Advisors LLC owned 0.90% of Scinai Immunotherapeutics worth $36,000 at the end of the most recent reporting period. 58.41% of the stock is currently owned by institutional investors.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.